ArticleBioactive materials2023
Fabrication, bacteriostasis and osteointegration properties researches of the additively-manufactured porous tantalum scaffolds loading vancomycin.
Article in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Recent advances in GelMA hydrogel transplantation for musculoskeletal disorders and related disease treatment.Theranostics · 2023Pooled it
- Direct ink writing of tantalum: tailorable hierarchical porous scaffold for osteogenesis.National science review · 2026Article
- Progress and challenges of tantalum-containing biomaterials in regenerative medicine applications.Journal of materials science. Materials in medicine · 2026Review
- Cell-derived vesicle-modified biomaterials for tissue repair and regeneration.Materials today. Bio · 2026Review
- Dynamic glucose-responsive mesoporous silica nanoparticle coating on trabecular tantalum implants for dual mode drug delivery.Materials today. Bio · 2026Article
- Multifunctional FePharmaceutics · 2026Article
- Article
- Emerging biomaterials for osteomyelitis treatment: from material design to anti-infection and tissue regeneration.Frontiers in cell and developmental biology · 2026Review
- Synergistic integration of biomaterials in orthopedic implantation for infection preventing and tissue engineering.Regenerative biomaterials · 2026Review
- A HMaterials today. Bio · 2025Article
- Strong living scaffolds for load-bearing musculoskeletal tissue regeneration.Materials today. Bio · 2025Review
- Bgh/GelMA/CMCS hydrogel with bone MSC-EVs for lunate defect repair.Nanomedicine (London, England) · 2025Article
- Advances in 3D-printed scaffold technologies for bone defect repair: materials, biomechanics, and clinical prospects.Biomedical engineering online · 2025Review
- New Direction in Antimicrobial Delivery System: Preparation and Applications of Hydrogel Microspheres.Pharmaceutics · 2025Review
- Innovative 3D-printed porous tantalum cage with non-window design to accelerate spinal fusion: A proof-of-concept study.Materials today. Bio · 2025Article
- Review
- Functional hydrogel empowering 3D printing titanium alloys.Materials today. Bio · 2025Review
- Evaluation of biological performance of 3D printed trabecular porous tantalum spine fusion cage in large animal models.Journal of orthopaedic translation · 2025Article
- 3D-printed artificial bone scaffolds: the design of materials, the incorporation of bioactive substances, and the integration of vascularized tissue flaps.Frontiers in bioengineering and biotechnology · 2025Review
- Advancements in GelMA bioactive hydrogels: Strategies for infection control and bone tissue regeneration.Theranostics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infected bone defects (IBDs) remains a challenging problem for orthopedists. Clinically, routine management for IBDs has two stages: debridement and systematic antibiotics administration to control infection, and secondary grafting to repair bone defects. Whereas the efficacy is not satisfactory, because the overuse of antibiotics may lead to systemic toxicity, and the emergence of drug-resistant bacteria, as well as the secondary surgery would cause additional trauma and economic burden to the patients. Therefore, it is imperative to develop a novel scaffold for one-stage repair of IBDs. In this study, vancomycin (Van) was encapsulated into poly(lactic co-glycolic acid) (PLGA) microspheres through the double emulsion method, which were then loaded into the additively-manufactured porous tantalum (AM-Ta) through gelatin methacryloyl (GelMA) hydrogel to produce the composite Ta/GelMA hydrogel (Gel)/PLGA/vancomycin(Van) scaffolds for repairing IBDs. Physiochemical characterization of the newly-developed scaffold indicated that the releasing duration of Van was over 2 weeks. Biological experiments indicated good biocompatibility of the composite scaffold, as well as bacteriostasis and osteointegration properties, which showed great potential for clinical application. The construction of this novel scaffold would provide new sight into the development of orthopaedic implants, shedding a novel light on the treatment of IBDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.